Tirzepatide from discovery to trial

The discovery paper

The 2018 report on LY3298176, the compound now called tirzepatide, contains several stages of the journey. Cell assays showed activity at GIP and GLP-1 receptors. In mice, the compound improved glucose control and reduced food intake and body weight. An early human programme involving 142 participants then supported further development and found reductions in fasting glucose and body weight versus placebo.

The early human arm earns my attention because it asks whether the mouse results survive a change of species. The candidate’s fatty-acid modification helped it bind albumin, a blood protein, and stay in circulation longer.

Receptor experiments

GIP and GLP-1 are gut hormones involved in the response to food. Tirzepatide activates both receptors, the receiving sites on cells. Its actions include glucose-dependent insulin release, glucagon suppression, slower stomach emptying and reduced appetite, as described in the clinical reference chapter.

The cell and islet experiments on receptor signalling found greater engagement of the GIP receptor than the GLP-1 receptor, with GLP-1 signalling favouring cAMP generation over beta-arrestin recruitment. “Dual” therefore covers an uneven pharmacological design. Two equal switches would be a tidier image than the one these experiments leave me with. The experiments describe a particular pattern of activity, while the clinical trials measure what happens to people.

Clinical comparisons

The 40-week SURPASS-2 trial enrolled 1,879 adults with type 2 diabetes. In that open-label comparison, tirzepatide produced greater reductions in weight and HbA1c than semaglutide. HbA1c reflects blood sugar over the preceding months. Gastrointestinal effects were the most common adverse events and were mostly mild or moderate.

The obesity programme asked a different clinical question. SURMOUNT-1 included 2,539 adults with obesity, or overweight with a weight-related complication, and without diabetes. At 72 weeks, mean weight changes ranged from −15.0% to −20.9% across the tirzepatide groups, compared with −3.1% with placebo. Stomach and bowel effects were common, mostly mild or moderate, and occurred chiefly during dose escalation.

In the later SURMOUNT-5 head-to-head trial, 751 adults with obesity and without type 2 diabetes received maximum tolerated doses of tirzepatide or semaglutide. At week 72, least-squares mean weight change was −20.2% with tirzepatide and −13.7% with semaglutide. The trial was open-label. I regard that direct comparison as a substantial result within its population and treatment conditions; an individual outcome still has to unfold in an individual person.

Safety signals

Reduced appetite can coexist with nausea, vomiting, constipation or diarrhea. Community accounts also describe fatigue, altered taste, hair shedding and changes in energy or sleep. Those anecdotal reports are not clinical evidence, and they cannot establish the cause or frequency of a symptom. The trial findings give the stomach and bowel effects a firmer basis.

A meta-analysis of nine trials involving 9,871 participants examined pancreatitis and gallbladder or biliary disease. The composite gallbladder-or-biliary-disease outcome increased significantly with tirzepatide versus controls; individual components did not show significant increases. The analysis found no statistically significant increase in pancreatitis. That result leaves uncertainty rather than establishing an absence of pancreatic risk.

The clinical reference also describes the prescribing warning about thyroid C-cell tumours, derived from rodent findings. The human relevance is unestablished. The contraindications include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Slowed stomach emptying can also affect other medicines, which makes the rest of a person’s treatment relevant to clinical assessment.

US prescription medicines

Particular tirzepatide medicines have FDA approval and require a prescription. The uses discussed here include type 2 diabetes and weight management in specified patients. The clinical reference covers the medicine’s mechanism, indications and safety; the trial papers describe their own populations and outcomes.

An imported research product or loose powder receives no approval from sharing the molecule’s name. Compounded medicines are not FDA-approved either. I separate the clinical programme’s success from the contents of a shipment, which still needs its own product-quality evidence.